Crizotinib impurity 27 CAS CATO-C4X-102527
| CAS No. | CATO-C4X-102527 |
| Molecular Formula | C21H22Cl2FN5O |
| Molecular Weight | 450.34 g/mol |
| Category | Pharmacopoeial Impurity Standards / EP Impurities |
| Availability | In Stock |
Chemical Structure
Description
Under current pharmacopoeial and regulatory frameworks, quality-control requirements for this class of reference material explicitly involve the control of targets including Crizotinib impurity 27.
As a process- or degradation-related impurity, Crizotinib impurity 27 (CAS CATO-C4X-102527, C21H22Cl2FN5O) is essential for impurity profiling, related-substances testing, and forced-degradation studies in pharmaceutical development.
Crizotinib impurity 27 (C21H22Cl2FN5O) contains a steroid core, an amide group, a hydroxyl group, an ether linkage, fluorine/chlorine substitution. Halogen substitution raises its density and boiling point; these physicochemical properties determine the optimal preparation and storage of its standard solutions. The presence of an aromatic ring or conjugated system gives the compound characteristic absorption bands in the UV-Vis region, making it well suited to UV or diode-array detection (DAD).
This reference standard supports related-substances testing and method development in line with ICH Q3A/Q3B guidance on impurity control, and is suitable for system suitability testing and forced-degradation studies.
CATO manufactures Crizotinib impurity 27 under ISO 17034:2016 accreditation with dual CNAS and ANAB accreditation. Each batch is characterized by orthogonal methods and supplied with a full Certificate of Analysis (COA), ensuring metrological traceability.
Physical & Chemical Properties
| Molecular Formula | C21H22Cl2FN5O |
| Molecular Weight | 450.34 g/mol |
| Appearance | Pale yellow to yellow crystalline powder. (slight halide-like odor, low volatility) |
| Purity | ≥95% |
| Storage | Store at room temperature, protect from light |
| Solubility (reference) | Soluble in DMSO, DMF, methanol |
| Stability | May oxidize slowly on prolonged air exposure; Light-sensitive; avoid direct strong light |
| Degree of Unsaturation (DBE) | 12.0 |
| UV Absorption | UV-absorbing |
| Structural Features | Aromatic ring present |
| Halogen Content | F/Cl-containing |
| Nitrogen Atoms | 5 |
Related Crizotinib Standards
- Crizotinib (CAS 877399-52-5)
- Crizotinib impurity 20 (CAS CATO-C4X-102520)
- Crizotinib S-Isomer (CAS 1374356-45-2)
- Crizotinib-d5 (CAS 1395950-84-1)
- Crizotinib impurity 34 (CAS CATO-C4X-102534)
- Crizotinib impurity 35 (CAS CATO-C4X-102535)
- Crizotinib impurity 40 (CAS CATO-C4X-102540)
- Crizotinib Impurity 51 (CAS CATO-C4X-102551)
Recommended Standards
- Sitagliptin Impurity 132 (CAS CATO-C4X-1144132)
- 3-(1-(2,6-Dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine (CAS 877400-66-3)
- N-(2-(3-bromo-2-hydroxynaphthalen-1-yl)-4-methoxy-3,5-dimethylphenyl)methanesulfonamide (CAS 1832514-09-6)
- N'-[(1Z)-(4-Methoxyphenyl)methylidene]-2,5-bis(2,2,2-trifluoroethoxy)benzohydrazide (CAS 477864-03-2)
- Fluorescein Impurity 10 (CAS CATO-C4X-290010)
- Finerenone Impurity 251 (CAS CATO-C4X-2880251)
- Cefathiamidine Impurity 17 (CAS CATO-C4X-133717)
- 169196-11-6 2,6-Diisopropyl-4-(4-fluorophenyl)-5-methoxymethylpyridine-3-carboxaldehyde 4-(4-Fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinecarboxaldehyde (CAS 169196-11-6)
- Terbutaline impurity 127 (CAS CATO-C4X-1183127)
- 1-(3-(Methylsulfonyl)pyridin-2-yl)ethanone (CAS 1269292-83-2)
- 3-Bromo-6-methoxypyrazolo[1,5-a]pyrimidine (CAS 1314893-99-6)
- 2-methyl-1-(pyrrolidin-1-yl)propan-2-amine (CAS 34155-39-0)
- 4-Bromo-7-fluoroquinoline (CAS 1070879-29-6)
- CBP501 Affinity Peptide trifluoroacetate salt (CAS 1351804-17-5)
Why CATO?
- ISO 17034 accredited reference material producer (CNAS + ANAB dual accreditation)
- 130,000+ catalog items in stock, COA supplied with every batch
- Worldwide shipping with full export documentation (HS code guidance available)
- Technical support: +86 18665070610 / Nicole.chen@cato-chem.com